Luke Evnin sold $64k of HOWL
director at Werewolf Therapeutics, Inc.. 100,581 shares at an average of $0.64, traded May 5, 2026, filed May 7, 2026.
Score components
- +15RoleDirector
- +8Trade size$64k at market
- 0Share of holdings soldSold 6.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001134657-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -6,860 | $0.69 | $4,733 | 1,672,470 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -14,635 | $0.66 | $9,659 | 1,657,835 | May 7, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -79,086 | $0.63 | $50k | 1,578,749 | May 7, 2026 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $47k 157,084 shares | -52% | |
| 5Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $28k 76,928 shares | -20% | |
| 6Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $43k 105,565 shares | -22% | |
| 8Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $64k 139,803 shares | -22% | |
| 8Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $66k 141,106 shares | -18% | |
| 9Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $87k 191,762 shares | -20% | |
| 8Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $76k 171,049 shares | -15% | |
| 0Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $24k 44,679 shares | -4% | |
| 19Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $280k 407,574 shares | -26% | |
| 12Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $198k 274,619 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.